Ronald Dullinger - 01 Jan 2026 Form 3 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Chief Commercial Officer
Signature
/s/ Alane P. Barnes, by power of attorney
Issuer symbol
BCRX
Transactions as of
01 Jan 2026
Net transactions value
$0
Form type
3
Filing time
09 Jan 2026, 19:19:54 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dullinger Ronald Chief Commercial Officer 4505 EMPEROR BLVD, SUITE 200, DURHAM /s/ Alane P. Barnes, by power of attorney 09 Jan 2026 0002103871

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BCRX Common Stock 258,372 01 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BCRX Emp. Stock Option (Right to Buy) 01 Jan 2026 Common Stock 100,000 $2.85 Direct F2
holding BCRX Emp. Stock Option (Right to Buy) 01 Jan 2026 Common Stock 100,000 $8.31 Direct F3
holding BCRX Emp. Stock Option (Right to Buy) 01 Jan 2026 Common Stock 41,000 $11.43 Direct F4
holding BCRX Emp. Stock Option (Right to Buy) 01 Jan 2026 Common Stock 57,100 $10.63 Direct F5
holding BCRX Emp. Stock Option (Right to Buy) 01 Jan 2026 Common Stock 57,100 $6.43 Direct F6
holding BCRX Emp. Stock Option (Right to Buy) 01 Jan 2026 Common Stock 68,500 $7.39 Direct F7
holding BCRX Emp. Stock Option (Right to Buy) 01 Jan 2026 Common Stock 255,050 $7.13 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 206,813 restricted stock units which vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
F2 Annual Employee Option Grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on November 29, 2019.
F3 Annual Employee Option Grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 15, 2020.
F4 Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 14, 2021.
F5 Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 19, 2022.
F6 Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 14, 2023.
F7 Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 19, 2024.
F8 Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 17, 2025.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney